The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2022 | Discovering drug resistance mechanisms in multiple myeloma & identifying novel treatment targets
Yael Cohen, MD, Tel-Aviv Sourasky Medical center, Tel-Aviv, Israel, outlines the different mechanisms of drug resistance in multiple myeloma, highlighting the possibility of finding new treatment targets using single-cell RNA sequencing (scRNA-seq). This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
